| Id: | acc4152 |
| Group: | 1sens |
| Protein: | AMPK |
| Gene Symbol: | Prkaa2 |
| Protein Id: | Q09137 |
| Protein Name: | AAPK2_RAT |
| PTM: | phosphorylation |
| Site: | Thr172 |
| Site Sequence: | MMSDGEFLRTSCGSPNYAAPE |
| Disease Category: | Endocrine and metabolic diseases |
| Disease: | Obese |
| Disease Subtype: | insulin resistance |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | rosiglitazone |
| Drug Info: | Rosiglitazone is a thiazolidinedione antidiabetic drug that works by improving insulin sensitivity. |
| Effect: | modulate |
| Effect Info: | "Rosiglitazone inhibits the expression and secretion of PEDF in adipose tissue and liver by promoting AMPK phosphorylation, which is closely related to the improvement of insulin resistance." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 24424059 |
| Sentence Index: | 24424059_11 |
| Sentence: | "However, rosiglitazone stimulated AMPK phosphorylation in fat and liver of the obese rats, whereas in vitro, when combined with compound C, the effect of rosiglitazone on PEDF was abrogated." |
Sequence & Structure:
MAEKQKHDGRVKIGHYVLGDTLGVGTFGKVKIGEHQLTGHKVAVKILNRQKIRSLDVVGKIKREIQNLKLFRHPHIIKLYQVISTPTDFFMVMEYVSGGELFDYICKHGRVEEVEARRLFQQILSAVDYCHRHMVVHRDLKPENVLLDAQMNAKIADFGLSNMMSDGEFLRTSCGSPNYAAPEVISGRLYAGPEVDIWSCGVILYALLCGTLPFDDEHVPTLFKKIRGGVFYIPEYLNRSIATLLMHMLQVDPLKRATIKDIREHEWFKQDLPSYLFPEDPSYDANVIDDEAVKEVCEKFECTESEVMNSLYSGDPQDQLAVAYHLIIDNRRIMNQASEFYLASSPPTGSFMDDMAMHIPPGLKPHPERMPPLIADSPKARCPLDALNTTKPKSLAVKKAKWHLGIRSQSKPYDIMAEVYRAMKQLDFEWKVVNAYHLRVRRKNPVTGNYVKMSLQLYLVDNRSYLLDFKSIDDEVVEQRSGSSTPQRSCSAAGLHRPRSSVDSSTAENHSLSGSLTGSLTGSTLSSASPRLGSHTMDFFEMCASLITALAR
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 172 | D | Type 2 diabetes | Phosphorylation | 33848515 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
